Piffaretti Gabriele, Franchin Marco, Gnesutta Aroa, Gatta Tonia, Piacentino Filippo, Rivolta Nicola, Lomazzi Chiara, Bissacco Daniele, Fontana Federico, Trimarchi Santi
Vascular Surgery-Department of Medicine and Surgery, University of Insubria School of Medicine, 21100 Varese, Italy.
ASST Settelaghi University Teaching Hospital, 21100 Varese, Italy.
J Clin Med. 2023 Dec 27;13(1):162. doi: 10.3390/jcm13010162.
To evaluate the feasibility of thoracic endovascular aortic repair (TEVAR) using the Ankura™ device (Lifetech Scientific, Shenzhen, China) with left subclavian artery (LSA) in-situ fenestration (ISF) using an adjustable puncture device system.
It is a single center, retrospective, financially unsupported cohort study of TEVAR performed from 16 February 2007 to 10 January 2023. Inclusion criteria were isolate LSA revascularization for elective or urgent/emergent "zone 2" TEVAR, and the availability of the preoperative computed tomography angiography.
Post-hoc analysis identified 52 TEVARs. There were 39 (75.0%) males, and 13 (25.0%) females: median age was 74.5 years (IQR, 65.5-78). Index TEVAR was performed for atherosclerotic aneurysm in 27 (51.9%) cases, dissection-related diseases in 18 (34.6%), penetrating aortic ulcer in 5 (9.6%), and blunt traumatic aortic injury in 2 (3.8%). Access-vessel feasibility rate of TEVAR using the Ankura™ device would have been 98.1% (51/52). Considering the morphology of the aortic arch, ISF TEVAR feasibility would have been 61.5% (32/52). Binary logistic regression analysis identified LSA angulation (OR: 1.1, 95%CI: 1.03-1.14, = 0.003) to be associated with ISF feasibility using this endograft and a self-centering adjustable needle-based puncture device.
Potential feasibility of TEVAR using the Ankura™ endograft with ISF using a self-centering adjustable needle system was 61.5%. Left subclavian artery angulation seems to be the most important and limiting anatomical constraint.
评估使用Ankura™装置(深圳微创医疗科学有限公司)行胸主动脉腔内修复术(TEVAR)并采用可调节穿刺装置系统对左锁骨下动脉(LSA)进行原位开窗(ISF)的可行性。
这是一项单中心、回顾性、无资金支持的队列研究,纳入了2007年2月16日至2023年1月10日行TEVAR的患者。纳入标准为因择期或紧急/急诊“2区”TEVAR而行孤立性LSA血运重建,且术前行计算机断层扫描血管造影检查。
事后分析确定了52例TEVAR。其中男性39例(75.0%),女性13例(25.0%);年龄中位数为74.5岁(四分位间距,65.5 - 78岁)。索引TEVAR用于治疗动脉粥样硬化性动脉瘤27例(51.9%),夹层相关疾病18例(34.6%),穿透性主动脉溃疡5例(9.6%),钝性创伤性主动脉损伤2例(3.8%)。使用Ankura™装置行TEVAR的入路血管可行率为98.1%(51/52)。考虑主动脉弓形态,ISF TEVAR可行率为61.5%(32/52)。二元逻辑回归分析确定LSA成角(比值比:1.1,95%置信区间:1.03 - 1.14,P = 0.003)与使用该血管内移植物和自定心可调节穿刺针装置的ISF可行性相关。
使用带有自定心可调节针系统的Ankura™血管内移植物行TEVAR并ISF的潜在可行性为61.5%。左锁骨下动脉成角似乎是最重要且具有限制作用的解剖学限制因素。